Why NCEL matters now
NewcelX Ltd. (NCEL) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.12 with +2.80% on the session and $1.4M in market capitalization; recent performance reads 1-month +4.09% and YTD +74.21%.
The latest financial table shown here is Q2 2025, with revenue of $0.00, net income of $-2.2M, and EPS of $-10.50. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -323.3%.
The latest indexable market news headline is "NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Revel Michel filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.46
P/S
0.00
EV/EBITDA
0.42
DCF Value
$10.10
FCF Yield
-323.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-101.0%
ROA
-49.9%
ROIC
-142.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $0.00 | $-2.2M | $-10.50 |
| Q4 2024 | $0.00 | $55.0K | $-9.90 |
| FY 2024 | $0.00 | $-2.0M | $-26.30 |
| Q2 2024 | $0.00 | $-2.0M | $0.00 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CH
Exchange
—
Beta
0.93
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.